一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Sacituzumab tirumotecan；Pembrolizumab；Supportive care measures，当前状态为招募中。登记地点显示中国合肥、北京、福州、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab tirumotecan；Pembrolizumab；Supportive care measures · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Second Affiliated hospital of Anhui Medical University ( Site 3133) · 合肥
- Beijing Cancer hospital-intrathoratic deparmtment II ( Site 3101) · 北京
- Beijing Peking Union Medical College Hospital-pneumology department ( Site 3100) · 北京
- Fujian Provincial Cancer Hospital ( Site 3131) · 福州
- The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 3107) · 厦门
- The First Affiliated Hospital of Guangzhou Medical University ( Site 3134) · 广州
- Southern Medical University Nanfang Hospital-Depatrment of Respiratory and Critical Care Medicine ( Site 3108) · 广州
- Affiliated Hospital of Guangdong Medical University ( Site 3123) · 湛江
- The Second Hospital of Hebei Medical University ( Site 3135) · 石家庄
- Harbin Medical University Cancer Hospital-oncology of department ( Site 3132) · 哈尔滨
- Henan Cancer Hospital ( Site 3116) · 郑州
- Tongji Hospital Tongji Medical,Science & Technology ( Site 3117) · 武汉
- Wuhan Union Hospital ( Site 3130) · 武汉
- Hubei Cancer Hospital ( Site 3106) · 武汉
- Xiangyang Central Hospital-oncology department ( Site 3136) · 襄阳
- The Second Xiangya Hospital of Central South University ( Site 3138) · 长沙
- Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3113) · 无锡
- The Affiliated Hospital of Xuzhou Medical College ( Site 3112) · 徐州
- The First Affiliated Hospital of Nanchang University-Respiratory Medicine Department ( Site 3127) · 南昌
- The Second Affiliated Hospital of Nanchang University-Oncology Department ( Site 3121) · 南昌
- Jiangxi Provincial Cancer Hospital ( Site 3143) · 南昌
- Jilin Province Tumor Hospital-oncology department ( Site 3126) · 长春
- Jinan Central Hospital-oncology department ( Site 3122) · 济南
- Shandong Cancer Hospital ( Site 3119) · 济南
- Shanghai Changhai Hospital ( Site 3125) · 上海
- West China Hospital, Sichuan University ( Site 3124) · 成都
- Sichuan Cancer hospital. ( Site 3105) · 成都
- The Second People's Hospital of Neijiang ( Site 3140) · 内江
- Yunnan Province Cancer Hospital ( Site 3139) · 昆明
- The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115) · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3111) · 杭州
- Taizhou Hospital of Zhejiang Province-Respiratory ( Site 3114) · 台州
公开的入选条件
- * Histologically or cytologically confirmed diagnosis of squamous or nonsquamous NSCLC
- Confirmation that epidermal growth factor receptor- (EGFR-), anaplastic lymphoma kinase- (ALK-), or proto-oncogene tyrosine-protein kinase ROS (ROS1-) directed therapy is not indicated as primary therapy
- Provided tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥50% of tumor cells as assessed by an immunohistochemistry (IHC) central laboratory
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 7 days before randomization.
- A life expectancy of at least 3 months.
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06170788；登记信息更新于 2026-09-17。